Standard medical therapy

Phase 3Small molecule

PPost Graduate Institute of Medical Education and Research, Chandigarh

Standard medical therapy is one of 115 small molecule programs targeting Arrhythmia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

MyocarditisActive, not recruiting

Chronic Liver FailureActive, not recruiting

EncephalopathyActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Systemic TherapyRecruiting

Peritoneal MetastasesNot yet recruiting

HypertensiveNot yet recruiting

ArrhythmiaPreclinical

Active, not recruiting

MyocarditisPreclinical

Active, not recruiting

Chronic Liver FailurePreclinical

Active, not recruiting

EncephalopathyPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Systemic TherapyPhase 2

Recruiting

Peritoneal MetastasesPhase 2

Not yet recruiting

HypertensivePreclinical

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Avastin

Gemzar

85 3

Domvanalimab

Arcus Biosciences

Phase 3

5 4

Standard medical therapy

PPost Graduate Institute of Medical Education and Research, Chandigarh

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Effectiveness

NCT06907056

Phase 2Recruiting

Systemic Therapy

NCT06655259

N/ANot yet recruiting

Hypertensive

NCT06790927

Q2 2027

Phase 3Not yet recruiting

Stroke

NCT07335107

Q3 2027

Not yet recruiting

Myocarditis

NCT07175948

Q2 2028

N/ANot yet recruiting

Arrhythmia

NCT07487532

Clinical

Trials by Indication[1]

Heart Failure3 trials

A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure

Completed·LLoneStar Heart, Inc.·Phase 2/3·NCT01311791·78 enrolled

Intravenous Iron Sucrose for Acute Decompensated Heart Failure Patients With Reduced Ejection Fraction and Iron Deficiency

Completed·—·Phase 4·NCT06703411·76 enrolled

A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

Unknown status·LLoneStar Heart, Inc.·N/A·NCT03082508·240 enrolled

Not yet recruiting·SSamsung Medical Center··NCT07393412·800,000 enrolled

18 more indications

Stroke1 trial

Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion

Not yet recruiting·—·Phase 3·NCT07335107·564 enrolled

Encephalopathy1 trial

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Completed·VVantive Health LLC·N/A·NCT00287235·70 enrolled

Coronary Artery Disease1 trial

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

Completed·—·Phase 4·NCT02681978·70 enrolled

Hypertensive1 trial

Standardized Antihypertensive Treatment Protocol

Not yet recruiting·SShanghai Jiao Tong University School of Medicine·N/A·NCT06790927·400 enrolled

Peritoneal Metastases1 trial

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

Not yet recruiting·IInstitut Cancerologie de l'Ouest·Phase 2·NCT06681038·114 enrolled

Effectiveness1 trial

Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico

Recruiting·JJosé Antonio Mata Marín·Phase 4·NCT06907056·138 enrolled

BIC/FTC/TAF1 trial

Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

Recruiting·JJosé Antonio Mata Marín·Phase 4·NCT07138144·156 enrolled

Myocarditis1 trial

Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital

Not yet recruiting·—··NCT07175948·100 enrolled

Systemic Therapy1 trial

Combination of TURP and Standard Systemic Therapy for MPCa

Recruiting·FFudan University·Phase 2·NCT06655259·200 enrolled

Ischemic stroke1 trial

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

Not yet recruiting·XXinqiao Hospital of Chongqing·Phase 3·NCT07347626·786 enrolled

Arrhythmia1 trial

Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation

Not yet recruiting·SShanghai Zhongshan Hospital·N/A·NCT07487532·120 enrolled

Ascites1 trial

Midodrine and Albumin in Patients With Refractory Ascites

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04621617·114 enrolled

Metastatic NSCLC1 trial

OMEGA, Local Ablative Therapy in Oligometastatic NSCLC

Unknown status·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 3·NCT03827577·195 enrolled

Non-Small Cell Lung Cancer1 trial

Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）

Active, not recruiting·SShanghai Chest Hospital·Phase 2/3·NCT07076693·97 enrolled

Type 2 Diabetes1 trial

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

Completed·—·Phase 4·NCT02742987·42 enrolled

Ventricular Function1 trial

Efficacy of Enhanced External Counterpulsation on Ventricular Function

Completed·SSun Yat-sen University·N/A·NCT03106116·150 enrolled

Chronic Liver Failure1 trial

To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03162419

Unspecified1 trial

InSite for Over Active Bladder

Completed·MMedtronicNeuro·Phase 4·NCT00547378·571 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Standard medical therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard medical therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard medical therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Post Graduate Institute of Medical Education and Research, Chandigarh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPost Graduate Institute of Medical Education and Research, Chandigarh

Standard medical therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q2 2028

Trials by Indication[1]

Heart Failure3 trials

Cirrhosis3 trials

Hepatitis2 trials

Cirrhosis of Liver1 trial

Long-term Follow-up1 trial

Stroke1 trial

Encephalopathy1 trial

Coronary Artery Disease1 trial

Hypertensive1 trial

Peritoneal Metastases1 trial

Effectiveness1 trial

BIC/FTC/TAF1 trial

Myocarditis1 trial

Systemic Therapy1 trial

Ischemic stroke1 trial

Arrhythmia1 trial

Ascites1 trial

Metastatic NSCLC1 trial

Non-Small Cell Lung Cancer1 trial

Type 2 Diabetes1 trial

Ventricular Function1 trial

Chronic Liver Failure1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News